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ABSTRACT
Objectives: In 2002, as part of a National Hospital Phar-
maceutical Strategy, the New Zealand (NZ) government
agency PHARMAC commenced a 3-year period of nego-
tiating prices for 90% of hospital pharmaceuticals on
behalf of all NZ public hospitals. The present study was
undertaken to determine the effects of this ﬁrst year of
“pooled procurement.”
Methods: Using price changes and volume data for each
of their top 150 pharmaceutical items, chief pharmacists
at 11 public hospitals calculated projected cost savings for
the ﬁnancial year July 2003 to June 2004. Researchers
calculated total projected savings for all 11 hospitals, and
for three types of hospitals. Estimates of projected savings
were made for all 29 major public hospitals by using
savings per bed and savings per bed-day. A sensitivity
analysis was undertaken. Items showing savings were cat-
egorized by using the Anatomical Therapeutic Chemical
classiﬁcation system.
Results: For the 11 hospitals, the top 150 items
comprised  612  different  items.  Projected  savings  for
2003 to 2004 were NZ$2,652,814, NZ$658,984, and
NZ$127,952 for tertiary, secondary, and rural/special
hospitals, respectively. Percentage savings as a median
(range)  of  the  total  top  150  expenditure  were:  terti-
ary 5.28% (3.09–16.05%), secondary 7.41% (4.67–
12.85%), and rural/special 9.55% (6.27–10.09%). For
all 29 hospitals, estimated projected savings were
NZ$5,234,919 (NZ$3,304,606–NZ$8,044,482) by sav-
ings per bed, and NZ$5,255,781 (NZ$2,936,850–
NZ$8,693,239) by savings per bed-day. The main con-
tributors to savings were: agents for infections, the
nervous system, musculoskeletal system, and blood/
blood-forming organs.
Conclusion: The ﬁrst year of pooled procurement under
the National Hospital Pharmaceutical Strategy (2002–
2003) has resulted in moderate savings. For all 29 major
public hospitals, savings of around NZ$5.2 million ($2.9
million–$8.7 million) or 3.7% were projected for 2003 to
2004. Longer-term effects, however, on patient outcomes
and availability of pharmaceuticals, as well as on phar-
maceutical expenditure, have yet to be evaluated.
Keywords: drug costs, group purchasing, hospitals, phar-
maceutical preparations, public.
Introduction
In recent decades, countries belonging to the
Organization for Economic Cooperation and
Development have seen pharmaceutical expendi-
ture rising steadily as a share of gross domestic
product, and averaging 15% of health-care expend-
iture (1970–1996) [1]. This growth has caused
concern for countries and health-care organizations
alike. Two main approaches have been used in an
attempt to control this growth, i.e., supply-side
management, and demand-side management [2–5].
Supply-side management focuses on negotiations
with vendors and may include price control, proﬁt
control, pooled procurement, rebates, reference
pricing, expenditure ceilings, or positive/negative
lists [5–16]. Demand-side management focuses on
the management of utilization of pharmaceuticals
by prescribers and patients and may include educa-
tional campaigns, prescribing guidelines, patient
copayments, switching prescription medicines to
over-the-counter medicines, promoting the use of
generics, devolution of budgets to practice level,
incentives/disincentives for prescribers, or regula-
tion of spending on promotion (also considered as
supply-side management) [3,4,6–9]. In 2003, May-
nard and Bloor indicated that despite the strategies
in place, there is scope for improved efﬁciency and
equity in the use of pharmaceuticals in most
countries [6].
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Since 1993, the Pharmaceutical Management
Agency (PHARMAC) in New Zealand (NZ) has
managed the Pharmaceutical Schedule––a list of
pharmaceutical products subsidized by the govern-
ment for prescribing for patients in the community.
By various means, but mainly by supply-side man-
agement, the agency has been successful in control-
ling pharmaceutical expenditure for patients in the
community [8]. In contrast to a number of other
developed nations, NZ has seen low growth in
recent years. From 1998 to 2002 the average annual
change in community pharmaceutical expenditure
was 1.46%, compared to 14.54% for the United
States, 9.7% for the United Kingdom, and 12.1%
(1998–2001) for Australia [17–20].
Expenditure on hospital pharmaceuticals has
been a sizable proportion of NZ’s total pharmaceu-
tical expenditure. In 2003, hospital pharmaceutical
expenditure was around $140 million compared
with $539 million for the government component
of expenditure on community pharmaceuticals, for
a population of 4 million people [21]. In February
2002, PHARMAC launched a National Hospital
Pharmaceutical Strategy (NHPS) to manage phar-
maceutical expenditure in public hospitals [22]. The
reduction of prices for pharmaceuticals or “price
management” was one of three major areas of
focus. Others were the assessment of new medicines
and promotion of quality use of medicines. The
agency proposed pooled procurement of frequently
used pharmaceuticals with the aim of reducing
national hospital pharmaceutical expenditure. Con-
sequently, during the ﬁrst year of implementation,
July 2002 to July 2003, new price contracts for all
hospitals were negotiated with suppliers for a
number of high volume medicines. Contracts were
implemented on a month-by-month basis, and items
were published in “Section H,” an additional phar-
maceutical schedule [23]. PHARMAC’s stated
intention was to negotiate new prices over a 3-year
period until approximately 90% of pharmaceuticals
used in hospitals were “Section H” items [22].
The majority of Section H items, because they
were frequently used hospital items, would be for
acute illness/surgical procedures. A smaller propor-
tion would be for continuation outside hospitals,
and PHARMAC intended, wherever possible, to
negotiate Section H and community contracts with
identical unit prices for such medicines. Hospitals
were expected to use the Section H brand for a
chemical entity selected, but were free to select
other chemical entities as clinically appropriate (i.e.,
were not obliged to use only Section H agents for
infections, anesthesia, etc.). To encourage compli-
ance with Section H contracts, hospitals were sub-
ject to ﬁnancial penalties from the suppliers of
Section H items if they purchased other brands of a
Section H chemical entity outside a small, speciﬁed
degree of variance (“discretionary variance limits”)
from the contract.
Pooled procurement has been implemented by
various countries and organizations to improve the
efﬁciency of purchase and distribution of pharma-
ceuticals; reports indicate moderate success [12–
16]. The effects of pooled procurement for NZ
hospitals as part of the NHPS have yet to be
determined.
Aim
The aim of the present study therefore was to
determine the effects of pooled procurement on
total hospital pharmaceutical expenditure resulting
from the ﬁrst year of implementation of the NHPS.
The objectives were to project possible savings for
2003 to 2004 for 11 public hospitals, and to esti-
mate the savings for 29 public hospitals. This study
is part of an ongoing evaluation of the impact of the
NHPS.
Methods
The 29 major public hospitals (i.e., employing one
or more pharmacists) in NZ were classiﬁed into
three types in an earlier project: tertiary, secondary,
and rural/special [24]. The NZ Ministry of Health
provided advice and validated the group alloca-
tions. Tertiary hospitals were those with all special-
ties on site; secondary, most specialties on site but
some visiting specialists; rural/special hospitals were
small hospitals with only visiting specialists or hos-
pitals for a special group of patients (e.g., psychiat-
ric). Thirteen of these hospitals were selected for the
present study as representative of the three types of
hospital and of different geographic localities.
The chief pharmacists at the 13 hospitals were
asked to provide the following ﬁnancial informa-
tion for the year July 1, 2002 to June 30, 2003:
1. a list of the top 150 pharmaceutical items by
annual expenditure (excluding total parenteral
nutrition products and ready-made chemother-
apy infusions);
2. the total expenditure for each of these items;
3. the total in-patient pharmaceutical expendi-
ture; and
4. new (Section H) prices for the top 150 items for
2002–2003.
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Because many individual prices for top 150 items
for 2001–2002 and 2002–2003 could not be dis-
closed to the researchers (they were conﬁdential to
suppliers and hospitals), the chief pharmacists were
also asked to calculate a projected cost savings for
each item for 2003–2004 by subtracting the 2002–
2003 price for each item from the 2001–2002 price
and multiplying by the volume used in 2002–2003.
Projections for 2003–2004 for each item were thus
based on actual price changes and the previous
year’s volume of use.
The following outcome measures were calculated
for each hospital, for each type of hospital, and for
all 11 hospitals that provided data: 1) the projected
overall savings as a percentage of the expenditure
on the top 150 items; and 2) the expenditure on the
top 150 items as a percentage of total inpatient
expenditure. Savings data for 11 hospitals were
used to estimate the projected overall savings for the
29 NZ public hospitals identiﬁed previously.
Two estimates of the above were made: by use of
projected savings per hospital bed, and by use of
projected savings per bed-day. The chief pharma-
cists provided information on the numbers of hos-
pital beds, and the Ministry of Health on numbers
of bed-days [24,25]. Projected savings were calcu-
lated by using stratiﬁcation by hospital type. A
sensitivity analysis was undertaken by stratiﬁcation
using the lowest and highest savings for each type of
hospital. Items showing savings, increased cost, or
no change were identiﬁed. Items with Section H
contract prices were identiﬁed by using the July
2003 Section H list. These items were categorized
by using the Anatomical Therapeutic Chemical
(ATC) classiﬁcation system developed by the World
Health Organization Collaborating Center on Drug
Statistics Methodology [26], ranked in order of pro-
jected savings, and tabulated by hospital type.
Results
Eleven hospitals (85%) provided data for the study.
(Data retrieval problems/time constraints prevented
two hospitals from participating.) Data were pro-
vided by ﬁve tertiary hospitals, three secondary hos-
pitals, and three rural/special hospitals. (Three
tertiary, two secondary, and two rural/special hos-
pitals were located in the more populous North
Island, and two tertiary, one secondary and one
rural/special hospitals in the South Island.)
Differences between the 11 hospitals in their
individual top 150 items resulted in a total list of
612 items. Of these, savings were projected for 157
items, increased costs for 128 items, and no change
for 327 items. Of the 612, 120 had a Section H con-
tract price in place by July 2003. Net projected
savings on the Section H items was $3,855,733. For
the remaining 492 items, a net increase in costs of
$415,983 was projected, thus overall net savings of
$3,439,749 were projected for the 11 hospitals.
Projected overall savings were $2,652,814,
$658,984, and $127,952 for tertiary, secondary,
and rural/special hospitals, respectively (Table 1).
For all 11 hospitals, median (range) savings repre-
sented 7.41% (3.09–16.05%) of expenditure on the
top 150 items. For the different types of hospitals,
savings were 5.28% (3.09–16.05%), 7.41% (4.67–
12.85%), and 9.55% (6.27–10.09%), for tertiary,
secondary, and rural/special hospitals, respectively.
The median savings per bed for each type of
hospital were $593, $509, and $378 (Table 2) for
tertiary, secondary and rural/special hospitals,
respectively, and median savings per bed-day were
$2.88, $3.01, and $2.25, respectively (Table 3).
Whether the estimated projected savings were based
on savings per bed or savings per bed-day made
little difference to the ﬁnal projection. For all 29
public hospitals these amounted to $5,234,919 by
savings per bed (Table 2), and $5,255,781 by sav-
ings per bed-day (Table 3). Sensitivity analysis
estimated ranges of $3,304,606–$8,044,483, and
$2,936,850–$8,693,239, respectively (Tables 2 and
3).
The main drivers of savings on items with Section
H contracts by ATC category were: agents for infec-
tions, the nervous system, musculoskeletal system,
Table 1 Projected overall savings for 11 selected hospitals
Type of  hospital
Top 150 
expenditure
(NZ$)
Projected 
savings (NZ$)
2003–2004
Projected savings
as percentage
of  top 150 items
(median, range) (%)
Total inpatient 
pharmaceutical 
expenditure (NZ$)
Top 150 as percentage
of  total inpatient
pharmaceutical
expenditure (median,
range) (%)
Tertiary 40,865,872 2,652,814 5.28 (3.09–16.05) 56,185,420 74 (71–80)
Secondary 7,038,897  658,984 7.41 (4.67–12.85) 10,364,494 70 (60–71)
Rural/special 1,523,595  127,952 9.55 (6.27–10.09) 2,856,273 73 (20–94)
All types 49,428,363 3,439,749 7.41 (3.09–16.05) 69,406,187 71 (20–94)
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and blood and blood-forming organs (Table 4). Pro-
jected savings ranged from 0.2% (V, Various) to
54.9% (J, Anti-infectives for systemic use). The
main contributors by ATC subcategories were:
antibiotics, psycholeptics  (antipsychotics),  general
and local anesthetics, treatments for bone disease
(bisphosphonates), blood substitutes, and analge-
sics. Bisphosphonates, plasma substitutes, and local
anesthetics had a proportionally greater effect on
projected savings for tertiary than on other hospi-
tals. Antipsychotics had a proportionally greater
effect on projected secondary hospitals savings, and
antibiotics and anesthetics on projected rural/
special hospital savings. Antibiotic savings were
mainly indicated for cephalosporins, penicillins, 4-
quinolones, and vancomycin. Savings on cetriaxone
(third generation cephalosporin) were indicated in
all types of hospitals. Savings on cefotaxime and
ceftazidime (third generation cephalosporin) and
cefuroxime (second generation) were indicated pre-
dominantly in tertiary and secondary hospitals.
Other chemical entities where projected savings
were greater than NZ$20,000 for the 11 hospitals
are highlighted in Table 5.
Discussion
The present study indicated that the price manage-
ment part of the NHPS will achieve moderate sav-
ings. Based on each hospital’s top 150 items, the
projected savings for 2003 to 2004 were $3.4 mil-
lion for the 11 hospitals studied. The estimated pro-
jected savings for the 29 major hospitals were $5.2
million, amounting to 3.7% of annual hospital
pharmaceutical expenditure. Both estimations of
projected savings were similar, whether based on
bed-days or bed numbers. Of the two estimations,
that based on bed-days was considered the most
valid because this would have captured the level of
activity of each hospital. The estimation based on
bed numbers would reﬂect only the bed capacity of
each hospital, and any days of spare capacity in a
particular hospital would give an overestimate for
that hospital.
Savings in the ﬁrst year of the NHPS appear to
have been achieved by targeting contracts to high
volume pharmaceuticals, such as antibiotics, gen-
eral and local anesthetics, antipsychotics, bisphos-
phonates, and blood substitutes. In all types of
hospital, over 50% of all savings were from antibi-
otics, and particularly for rural/special hospitals
(64%). The extent of overall savings in forthcoming
years remains to be determined, but savings are
likely to be smaller when lower volume pharmaceu- Ta
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ticals are targeted. Because generic versions of a
bisphosphonate and a few antibiotics became avail-
able between 2001 and 2002, some savings may
have resulted regardless of the strategy [27]. The
impact of this on estimated projected savings for all
hospitals would probably be small, considering that
hospitals using these generic versions prior to the
strategy still indicated substantial savings on these
particular items.
A wider range of pharmaceuticals drove savings
in the tertiary hospitals than in other hospitals,
probably reﬂecting the different patient proﬁles and
patterns of drug use. Differences between tertiary
hospitals probably reﬂected the same factors. An
example of the latter would be the lower savings
indicated for the tertiary hospitals that were
national/regional centers for transplantation. The
expensive therapies used achieved “Top 150 status”
and would have diluted the effects of savings on
more widely used drugs such as antibiotics and
anesthetics. In addition, some of these hospitals
may have had lower baseline prices in 2001–2002;
their high volumes of use probably resulted in
stronger bargaining power.
Although all hospitals providing data indicated
that savings would be achieved, there were winners
and losers in the hierarchy. The median projected
savings were greater for the rural/special hospitals
and secondary hospitals than for tertiary hospitals.
This was as expected because these hospitals prob-
ably had less bargaining power and less attractive
contracts in place before the NHPS was imple-
mented. There were large variations in projected
savings within the types of hospitals. These proba-
bly reﬂect prior contracting arrangements, extent of
use of items now available at lower prices, and over-
all patterns of drug use.
Individual items driving savings differed between
types of hospital. As expected, agents for acute/
serious illness or surgery appeared to drive savings
in tertiary hospitals: vancomycin, local anesthetics,
general anesthetics (isoﬂurane, propofol), atracu-
rium, pamidronate, ﬁlgrastrim, and methylpred-
nisolone. Also as expected, agents for severe
infections  appeared  to  drive  savings  for  tertiary
and secondary hospitals: ﬂucloxacillin, cefuroxime
(second generation cephalosporin), cefotaxime and
ceftazidime (both third generation cephalosporins).
Co-amoxiclav, ciproﬂoxacin, and ceftriaxone (third
generation cephalopsorin) appeared to drive savings
in all types of hospital.
The present study concurs with other studies
indicating that pooled procurement was a successful
means of pharmaceutical cost containment [12–16].
Over time, however, declining compliance with con-
tracts could reduce savings. This was an issue in an
NZ pooled procurement initiative in 1980, and it
has also been an issue in the United Kingdom and
United  States  [12,15,28].  PHARMAC’s  system
of ﬁnancial penalties for hospitals exceeding “dis-
cretionary variance limits” on contract items will
encourage hospitals to comply with contracts. It is
hoped that compliance should not be an issue unless
there are unforeseen quality or availability prob-
lems, but the ﬁnancial cost of penalties to hospitals
needs to be monitored in the future.
This present study aims to determine the ﬁnan-
cial impact of the price management part of the
NHPS. Price management could also impact on
product availability, and on pharmaceutical suppli-
ers. If quality or availability of products were
affected, alternative items may be used and this may
impact on pharmaceutical expenditure (cost shift-
ing) or on patient outcomes. If some products were
Table 5 Chemical entities driving projected savings for all 11 selected hospitals
Anatomic therapeutic category
Chemical entities where projected savings were greater
than NZ$20,000
Hospitals predominantly
projecting savings
Anti-infectives for systemic use J Co-amoxiclav, ciproﬂoxacin All
Vancomycin Tertiary
Flucloxacillin Tertiary and secondary
Ceftriaxone (3rd generation cephalosporin) All
Cefotaxime, ceftazidime (third generation cephalosporins) Tertiary and secondary
Cefuroxime (second generation cephalosporin) Tertiary and secondary
Nervous system N Local anesthetics, and some anesthetics (isoﬂurane, propofol) Tertiary
Sevoﬂurane, citalopram, clozapine Tertiary and secondary
Tramadol Tertiary and secondary
Musculoskeletal system M Atracurium, pamidronate Tertiary
Blood and blood-forming organs B Gelofusine, pentastarch Tertiary and secondary
Alimentary tract and metabolism A Ondansetron Tertiary and secondary
Systemic hormonal preparations
excluding sex hormones and insulin
H Methylprednisolone Tertiary
Antineoplastic/immunomodulating L Filgrastim Tertiary
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withdrawn as a result of this policy, clinical choice
would be reduced. These aspects, particularly any
impact on patient outcomes, need to be monitored
by hospital pharmacists and doctors, and evaluated
in the future.
Although countries and health-care organiza-
tions have implemented various strategies to reduce
pharmaceutical expenditure in recent decades [3–
16], there is little hard evidence on which to com-
pare their success. Demand-side strategies, attempt-
ing to reduce volumes of prescribed items are
increasingly popular, particularly formularies and
guidelines in the United States and Europe [16,29–
31]. Their impact, however, is difﬁcult to quantify.
In NZ, volumes of prescribed drugs have risen mod-
erately, while overall expenditure has risen slowly
[32]. PHARMAC has demand-side strategies in
place for community prescribing and is discussing
initiatives for hospitals. Their impact will need to be
evaluated in the future.
There were some limitations to the study. There
was limited access to prices for pharmaceuticals
because of the existence of conﬁdentiality agree-
ments between suppliers and hospitals and, as a
result, chief pharmacists or their staff undertook cal-
culations of cost savings for each top 150 item. The
accuracy of each individual calculation could not be
veriﬁed by the researchers; however, some accuracy
checks were undertaken: chief pharmacists were
asked to recalculate costs savings for items where
other hospitals showed savings, and to recheck
prices if a Section H price existed but were not noted
on their spreadsheet. Approximately 70% (Top 150
items) of hospital pharmaceutical expenditure was
used to derive a projected saving. Other authors rec-
ommend targeting the top 70% to 80% of expend-
iture for price reductions because changes in the
lower 20% to 30% make little overall difference
[33]. Targeting 100% of pharmaceutical expendi-
ture per hospital, about 2500 items, would have
allowed a more accurate projection, but time and
resource constraints prohibited this. A subset of 11
hospitals provided data rather than all 29 hospitals.
These were hospitals with the resources and appro-
priate computer systems to participate, but they rep-
resented all types of hospitals, 58% of hospital beds,
and 62% of bed-days. The present study may under-
estimate the savings resulting from the price man-
agement part of the NHPS because PHARMAC
proposed to implement a conﬁdential rebate system
as part of this process. The extent of savings from
rebates cannot be determined at present because
individual rebates remain conﬁdential and overall
hospital rebates have yet to be published.
Conclusion
The ﬁrst year of pooled procurement under the
NHPS (2002–2003) has resulted in moderate cost
savings. As a result of contracts negotiated from
2002 and to 2003, savings of around $5.2 million
($2.9 million–$8.7 million) or 3.7% were projected
for 29 hospitals for 2003 to 2004. As a proportion
of expenditure, median savings were greater in the
rural/special hospitals. Longer-term effects, how-
ever, on patient outcomes, as well as on pharmaceu-
tical expenditure, range of available medicines, and
effects on suppliers, have yet to be evaluated.
The authors are grateful to the chief pharmacists partici-
pating in the study. There were no external sources of
funding for the project, and there are no potential con-
ﬂicts of interest to declare.
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